Dark pools may be responsible for recent overselling w/2 near-term catalysts: 4/25 (presentation of its Phase 1b PD drug results at AAN Annual Meeting), 5/11 (earnings). Its PD (VY-AADC01) will shake the market if its phase 1b results can be replicated. Price should correct to $14-15 after a couple weeks.
VYGR
VYGR
Komen:
My position remains unchanged.